Wegovy FlexTouch 1mg Solution for Injection in Pre-Filled Pen + 4mm Needles (4)
Contains 1.34 mg/mL of semaglutide*. Each dose contains 1mg of semaglutide in 0.75mL solution. One pre-filled pen contains 4.0 mg (four doses) of semaglutide in 3 mL solution

Adults

Wegovy is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial Body Mass Index (BMI) of

• ≥30 kg/m2 (obesity), or
• ≥27 kg/m2 to <30 kg/m2 (overweight) in the presence of at least one weight-related comorbidity.

Adolescents (≥12 years)

Wegovy is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adolescents ages 12 years and above with obesity* or body weight above 60 kg.

Treatment with Wegovy should be discontinued and re-evaluated if adolescent patients have not reduced their BMI by at least 5% after 12 weeks on the 2.4 mg or maximum tolerated dose.

Cardiovascular Risk Reduction

Wegovy is indicated as an adjunct to a reduced-calorie diet and increased physical activity to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established cardiovascular disease and either obesity or overweight (BMI ≥ 27 kg/m2).

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Wegovy 1 mg, FlexTouch solution for injection in pre-filled pen - Summary of Product Characteristics (SmPC) - (emc) (medicines.org.uk)